Stock listing
NASDAQ:FDMT 4D Molecular Therapeutics, Inc. Stock
Home listing (NASDAQ) of 4D Molecular Therapeutics, Inc.
Follow 4D Molecular Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:FDMT
$10.23 USD -0.23 (-2.2%)
Close on Nov 20, 2026
- Day range
- $10.11 – $10.94 USDNov 20, 2026
- Volume
- 690,941 sharesNov 20, 2026
- Market cap
- $565.1M USDAt the close on Nov 20, 2026 · price × 55.24M shares outstanding
- 52-week range
- $6.96 – $16.93 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13.13M USDMedian day 897,223 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:FDMT · Home | $10.23 USD | -0.23 (-2.2%) | 690,941 | $10.36 | $10.94 | $10.11 | $10.46 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FDMT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.23 | -0.23 | -2.2% | $10.36 | $10.94 | $10.11 | 690,941 | |
| $10.46 | -0.33 | -3.1% | $10.77 | $10.99 | $10.30 | 679,298 | |
| $10.79 | -0.50 | -4.4% | $11.33 | $11.49 | $10.54 | 813,812 | |
| $11.29 | -0.94 | -7.7% | $12.25 | $12.34 | $11.22 | 968,930 | |
| $12.23 | +0.115 | +0.9% | $11.66 | $12.37 | $10.98 | 813,801 | |
| $12.12 | -0.875 | -6.7% | $12.59 | $12.86 | $12.05 | 897,223 | |
| $12.99 | +0.53 | +4.3% | $12.48 | $13.03 | $12.38 | 837,170 | |
| $12.46 | -0.02 | -0.2% | $12.43 | $12.76 | $12.15 | 1,075,502 | |
| $12.48 | +0.23 | +1.9% | $12.42 | $12.71 | $12.15 | 879,758 | |
| $12.25 | +1.00 | +8.9% | $11.46 | $12.57 | $11.28 | 993,257 | |
| $11.25 | -1.03 | -8.4% | $12.11 | $12.11 | $11.16 | 1,598,595 | |
| $12.28 | +0.33 | +2.8% | $12.36 | $12.42 | $11.55 | 764,654 | |
| $11.95 | +0.58 | +5.1% | $11.52 | $12.08 | $11.46 | 740,402 | |
| $11.37 | -0.53 | -4.5% | $11.88 | $12.06 | $11.16 | 734,781 | |
| $11.90 | -0.88 | -6.9% | $12.49 | $12.88 | $11.74 | 683,476 | |
| $12.78 | -0.15 | -1.2% | $13.00 | $13.46 | $12.57 | 848,889 | |
| $12.93 | +0.97 | +8.1% | $11.89 | $12.96 | $11.73 | 1,189,747 | |
| $11.96 | +0.93 | +8.4% | $10.96 | $11.99 | $10.75 | 1,134,654 | |
| $11.03 | +0.23 | +2.1% | $10.74 | $11.29 | $10.62 | 1,084,577 | |
| $10.80 | -1.05 | -8.9% | $11.74 | $11.75 | $10.68 | 996,140 | |
| $11.85 | -0.77 | -6.1% | $12.60 | $13.12 | $11.68 | 1,354,686 | |
| $12.62 | -0.48 | -3.7% | $13.12 | $13.45 | $12.61 | 2,019,208 | |
| $13.10 | +0.81 | +6.6% | $12.29 | $13.39 | $12.29 | 725,371 | |
| $12.29 | +0.15 | +1.2% | $12.36 | $12.68 | $12.21 | 855,679 | |
| $12.14 | -0.73 | -5.7% | $12.84 | $12.84 | $12.00 | 794,500 | |
| $12.87 | +0.67 | +5.5% | $12.30 | $13.01 | $12.04 | 787,600 | |
| $12.20 | -0.16 | -1.3% | $12.18 | $12.58 | $11.99 | 633,000 | |
| $12.36 | -0.64 | -4.9% | $12.91 | $12.91 | $12.25 | 991,700 | |
| $13.00 | -0.33 | -2.5% | $13.30 | $13.47 | $12.86 | 835,800 | |
| $13.33 | +0.63 | +5.0% | $12.70 | $13.85 | $12.55 | 867,900 | |
| $12.70 | +0.11 | +0.9% | $12.42 | $12.74 | $12.12 | 970,800 | |
| $12.59 | +0.03 | +0.2% | $12.36 | $12.92 | $12.19 | 603,600 | |
| $12.56 | -0.36 | -2.8% | $12.64 | $13.02 | $12.30 | 1,170,900 | |
| $12.92 | -0.75 | -5.5% | $13.86 | $13.86 | $12.61 | 2,110,300 | |
| $13.67 | -0.17 | -1.2% | $14.12 | $14.14 | $13.60 | 1,036,900 | |
| $13.84 | -0.47 | -3.3% | $14.23 | $14.58 | $13.80 | 655,500 | |
| $14.31 | -0.18 | -1.2% | $14.76 | $14.83 | $14.08 | 1,037,100 | |
| $14.49 | -0.07 | -0.5% | $14.70 | $14.97 | $13.94 | 1,376,000 | |
| $14.56 | +0.09 | +0.6% | $14.36 | $14.82 | $13.92 | 1,557,400 | |
| $14.47 | -0.24 | -1.6% | $14.78 | $14.82 | $14.03 | 1,018,000 | |
| $14.71 | -0.29 | -1.9% | $14.81 | $14.98 | $13.56 | 1,767,900 | |
| $15.00 | -0.88 | -5.5% | $15.97 | $15.97 | $14.68 | 1,465,500 | |
| $15.88 | +0.64 | +4.2% | $15.21 | $16.23 | $15.13 | 936,600 | |
| $15.24 | +0.02 | +0.1% | $15.57 | $15.70 | $14.68 | 699,100 | |
| $15.22 | +0.54 | +3.7% | $15.12 | $15.69 | $14.78 | 1,787,500 | |
| $14.68 | +0.92 | +6.7% | $13.93 | $14.87 | $13.93 | 930,600 | |
| $13.76 | +0.13 | +1.0% | $13.65 | $14.20 | $13.55 | 819,600 | |
| $13.63 | -0.13 | -0.9% | $13.95 | $13.95 | $13.18 | 552,000 | |
| $13.76 | +0.59 | +4.5% | $13.64 | $14.19 | $13.43 | 977,200 | |
| $13.17 | -0.32 | -2.4% | $13.69 | $14.02 | $12.94 | 481,100 | |
| $13.49 | -0.69 | -4.9% | $13.88 | $14.02 | $13.40 | 566,100 | |
| $14.18 | -0.45 | -3.1% | $14.44 | $14.50 | $14.09 | 493,800 | |
| $14.63 | -0.34 | -2.3% | $14.57 | $15.29 | $14.13 | 542,000 | |
| $14.97 | +0.27 | +1.8% | $14.50 | $15.00 | $14.33 | 420,600 | |
| $14.70 | -0.24 | -1.6% | $14.94 | $14.94 | $14.28 | 782,400 | |
| $14.94 | +0.59 | +4.1% | $14.40 | $15.13 | $14.08 | 1,035,900 | |
| $14.35 | +0.24 | +1.7% | $13.94 | $14.85 | $13.80 | 708,000 | |
| $14.11 | -0.56 | -3.8% | $14.49 | $14.60 | $13.67 | 1,404,200 | |
| $14.67 | -0.24 | -1.6% | $14.92 | $15.00 | $14.20 | 1,101,300 | |
| $14.91 | -0.65 | -4.2% | $15.44 | $15.77 | $14.82 | 717,600 | |
| $15.56 | -0.16 | -1.0% | $15.50 | $15.67 | $15.04 | 717,900 | |
| $15.72 | +0.33 | +2.1% | $15.69 | $16.34 | $15.42 | 919,118 | |
| $15.39 | -0.44 | -2.8% | $15.68 | $15.83 | $14.35 | 1,474,743 | |
| $15.83 | -0.27 | -1.7% | $16.32 | $16.91 | $15.33 | 918,700 | |
| $16.10 | -0.66 | -3.9% | $16.50 | $16.71 | $15.63 | 1,630,800 |
- Ticker
- NASDAQ:FDMT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
4DMT Announces New Employment Inducement Grants
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 60 slides
Latest news
4DMT Announces New Employment Inducement Grants
Nov 13, 2026
Closed $11.29 (-7.7%) on Nov 16, 2026
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Nov 12, 2026
Closed $12.23 (+0.9%) on Nov 13, 2026
4DMT to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $11.95 (+5.1%) on Nov 3, 2026
4DMT to Host Investor Day on October 21, 2026
Oct 5, 2026
Closed $12.92 (-5.5%) on Oct 5, 2026
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
Sep 28, 2026
Closed $14.56 (+0.6%) on Sep 28, 2026
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Aug 13, 2026
Closed $12.19 (+4.6%) on Aug 14, 2026
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Jul 18, 2026
Closed $11.09 (+0.9%) on Jul 20, 2026
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
Jun 30, 2026
Closed $12.69 (-4.6%) on Jul 1, 2026
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
Jun 29, 2026
Closed $12.88 (+11.0%) on Jun 29, 2026
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
Jun 29, 2026
Closed $12.88 (+11.0%) on Jun 29, 2026
4D Molecular Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 131 in all · newest Nov 13, 2026 · oldest 2020
- Decks
- 24 decks · latest September 2026
Where 4D Molecular Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:FDMT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:FDMT | BOATS | United States | USD |
Valuation
EV/sales 2.9× against a median of 47.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $277.8M USD
- P/E
- Loss
- EV/sales
- 2.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- 4.8%
- Operating margin
- −226.0%
- Net margin
- −208.6%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.75
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Design Therapeutics, Inc. · NASDAQ:DSGN | US$577.6M | US$371.5M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.29 |
| Cullinan Therapeutics, Inc. · NASDAQ:CGEM | US$577.1M | US$289.6M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 1.45 |
| Immix Biopharma, Inc. · NASDAQ:IMMX | US$577.0M | US$241.7M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.60 |
| Entera Bio Ltd. · NASDAQ:ENTX | US$574.8M | US$308.9M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | 0.76 |
| DBV Technologies SA · EURONEXT:DBV | US$571.8M | US$430.7M | n/a | 47.1× | n/a | 3.9× | n/a | 0.1× | n/a |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.3M | US$232.4M | n/a | 765× | n/a | 1.7× | n/a | 0.0× | n/a |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Lepu Biopharma Co. Ltd. Class H · HKEX:2157 | US$554.8M | US$613.4M | 14.6× | 4.5× | 22.9× | 2.6× | 28.0% | 0.8× | n/a |
| Aclaris Therapeutics, Inc. · NASDAQ:ACRS | US$545.6M | US$431.3M | n/a | 67.4× | n/a | 3.3× | n/a | 0.0× | 1.42 |
| ArriVent BioPharma, Inc. · NASDAQ:AVBP | US$544.1M | US$151.2M | n/a | 30.2× | n/a | 1.4× | n/a | 0.0× | 1.18 |
| Median of the others | US$571.6M | US$299.3M | 14.6× | 47.1× | 22.9× | 2.1× | 28.0% | 0.0× | 1.37 |
Forecasts
9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 28.09 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.14 · 10 analysts
- Revenue, year to Dec 2026
- 13.25M · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David Kirn | Chief Executive Officer, President, and Co-Founder |
| Kristian Humer | Chief Financial Officer |
| Scott Bizily | Chief Legal Officer |
| Chris Simms | Chief Commercial & Business Officer |
| Dhaval Desai | Chief Development Officer |
| John F. Milligan | Executive Chairman |
| Julie Clark | Chief Medical Officer |
| Katy Barglow | Chief Technical Officer |
| Kim Maplestone | Chief Clinical Operations Officer |
| Theresa Janke | Chief of Staff, Co-Founder |
Board
| Director | Role |
|---|---|
| John F. Milligan | Executive Chairman |
| Charles Theuer | Director |
| Glenn P. Sblendorio | Board Member |
| Jacob Chacko | Director |
| Nancy Miller-Rich | Board Member |
| Shawn Tomasello | Director |
| Susannah Gray | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +0.9% |
| Q2 2026 | Aug 13, 2026 · After close | +4.6% |
| Q1 2026 | May 7, 2026 · After close | +2.1% |
| Q4 2025 | Feb 27, 2026 | −3.4% |
| Q3 2025 | Nov 10, 2025 · Before open | −3.1% |
| Q2 2025 | Aug 11, 2025 · Before open | −1.8% |
| Q1 2025 | May 8, 2025 · After close | −4.9% |
| Q4 2024 | Feb 26, 2025 · Before open | +5.7% |
| Q3 2024 | Nov 13, 2024 · After close | +4.0% |
| Q2 2024 | Aug 8, 2024 · After close | +0.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +0.2% |
| Q4 2023 | Feb 29, 2024 · After close | +4.8% |
| Q3 2023 | Nov 9, 2023 · After close | +5.2% |
| Q2 2023 | Aug 9, 2023 · After close | −2.3% |
| Q1 2023 | May 10, 2023 · After close | −4.3% |
| Q4 2022 | Mar 15, 2023 · After close | +5.7% |
| Q3 2022 | Nov 8, 2022 · After close | +6.4% |
| Q2 2022 | Aug 11, 2022 · After close | −8.3% |
| Q1 2022 | May 12, 2022 · After close | −4.3% |
| Q4 2021 | Mar 28, 2022 · After close | +6.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 60 slides | September 2026 |
| Technical Presentation (May 2026) | Technical | 12 slides | May 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 39 slides | January 2026 |
| Technical Presentation (December 2025) | Technical | 65 slides | Dec 17, 2025 |
| Technical Presentation (July 2025) | Technical | 12 slides | July 2025 |
| Bank of America 2025 Healthcare Conference | Conference | 22 slides | May 2025 |
| Technical Presentation (January 2025) | Technical | 16 slides | Jan 10, 2025 |
| Technical Presentation (2025) | Technical | 16 slides | 2025 |
| EURETINA 2024 | Conference | 17 slides | September 2024 |
| Retina Society 2024 | Conference | 14 slides | September 2024 |
All 24 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2024) | Investor deck | 77 slides | August 2024 |
| ASRS 2024 | Conference | 13 slides | Jul 15, 2024 |
| Clinical Trials at the Summit (June 2024) | Conference | 10 slides | Jun 6, 2024 |
| 47th European Cystic Fibrosis Conference (ECFS 2024) | Conference | 22 slides | Jun 5, 2024 |
| Technical Presentation (April 2024) | Technical | 15 slides | Apr 20, 2024 |
| Gene Therapy for Ophthalmic Disorders Summit 2023 | Conference | 25 slides | Nov 28, 2023 |
| Fact Sheet (September 2023) | Fact sheet | 2 slides | Sep 22, 2023 |
| Technical Presentation (July 2023) | Technical | 15 slides | July 2023 |
| ASGCT Symposium 2023 | Conference | 33 slides | May 18, 2023 |
| ARVO 2023 | Conference | 17 slides | April 2023 |
| Investor Presentation (January 2022) | Investor deck | 35 slides | Jan 11, 2022 |
| Technical Presentation (2021) | Technical | 9 slides | 2021 |
| Technical Presentation (2021) | Technical | 17 slides | 2021 |
| ASGCT 2021 | Conference | 14 slides | 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of equity Closed: US$93M raised · US$10.51 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Evercore ISI (co-lead), Cantor (co-lead), RBC Capital Markets Use of proceeds: Fund planned operations into 2H 2028, including a planned 4D-150 Phase 3 trial in diabetic macular edema | Nov 10, 2025 |
| Strategic investment of 4DMT equity Tranche closed: US$7.5M raised Buyers: Cystic Fibrosis Foundation (up to $11 million in 4DMT equity in two tranches; first tranche of $7.5 million closed) Use of proceeds: Accelerate development of 4D-710 for cystic fibrosis: second dosing in Phase 1, advancement into Phase 2, and Phase 3 readiness | Oct 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$23.00 a share on Dec 10, 2020.
- Price
- US$23.00 a share
- Shares offered
- 8,400,000 shares of common stock
- Offering size
- US$193.2 million
- Underwriters' option
- Up to 1,260,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, BofA Securities, Evercore ISI · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 14, 2020 |
| Filed publicly | Nov 17, 2020 |
| Amended twice | Newest Dec 10, 2020 |
| Shares registered with an exchange | Dec 8, 2020 |
| Declared effective by the SEC | Dec 10, 2020 |
| Final prospectus, with the price | Dec 14, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 14, 2020 |
| UPLOAD · Letter from the SEC | Dec 11, 2020 |
| EFFECT · Notice that a registration is effective | Dec 10, 2020 |
| S-1MEF · Registration of more shares for the same offering | Dec 10, 2020 |
| CERT · Exchange's certificate of listing | Dec 10, 2020 |
| S-1/A · Registration statement, amended | Dec 10, 2020 |
| CORRESP · Letter to the SEC | Dec 8, 2020 |
| CORRESP · Letter to the SEC | Dec 8, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 8, 2020 |
| CORRESP · Letter to the SEC | Dec 7, 2020 |
All 15 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Dec 7, 2020 |
| UPLOAD · Letter from the SEC | Dec 4, 2020 |
| CORRESP · Letter to the SEC | Nov 17, 2020 |
| S-1 · Registration statement | Nov 17, 2020 |
| DRS · Draft registration statement | Oct 14, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 14, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.2M | 37.0K | 20.7M | 3.13M | 18.0M | 13.6M | 6.99M | 14.1M | 5.79M |
| Cost of revenue | 7.63M | 141.3M | 97.1M | 3.88M | 3.02M | 53.0M | 38.7M | 18.4M | 13.6M |
| Gross profit | 77.6M | -141.3M | -76.4M | 3.13M | 18.0M | -39.4M | -31.7M | -4.23M | -7.78M |
| Research and development | 195.7M | 141.3M | 97.1M | 80.3M | 61.4M | 53.0M | 38.7M | 18.4M | 13.6M |
| Selling, general and administrative | 49.1M | 46.6M | 36.5M | 32.9M | 28.0M | 17.2M | 13.9M | 6.17M | 3.49M |
| Operating income | -159.5M | -187.8M | -112.9M | -110.0M | -71.3M | -56.7M | -50.8M | -10.4M | -11.3M |
| Depreciation and amortization | 4.69M | 4.65M | 4.20M | 2.40M | 1.52M | 1.44M | 1.00M | 697.0K | 626.0K |
| EBITDA | -154.9M | -183.2M | -108.7M | -107.6M | -69.8M | -55.2M | -49.8M | -9.70M | -10.6M |
| Interest expense | 6.42M | 3.04M | 152.0K | 0 | 0 | 0 | |||
| Income before tax | -140.1M | -160.9M | -100.8M | -107.5M | -71.3M | -56.7M | -49.3M | -9.55M | -11.2M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 3.63M | 848.0K | -89.0K |
| Net income | -140.1M | -160.9M | -100.8M | -107.5M | -71.3M | -56.7M | -49.3M | -9.55M | -11.2M |
| Earnings per share, basic | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 | -9.59 | -0.76 | -0.76 |
| Earnings per share, diluted | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 | -9.59 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 60.2M | 149.3M | 249.1M | 52.4M | 153.0M | 276.7M | 49.7M | 91.8M | 23.9M |
| Short-term investments | 342.4M | 275.5M | 39.1M | 161.2M | 94.8M | 0 | |||
| Receivables | 0 | 47.0K | 1.49M | 978.0K | 1.12M | 321.0K | |||
| Inventory | -5.79M | -8.50M | 1 | ||||||
| Current assets | 413.1M | 434.9M | 296.6M | 220.5M | 256.3M | 282.7M | 52.5M | 94.1M | 24.5M |
| Property, plant and equipment | 14.9M | 19.5M | 20.1M | 22.3M | 14.4M | 5.07M | 5.05M | 2.47M | 2.72M |
| Total assets | 566.7M | 560.4M | 339.9M | 261.8M | 353.5M | 288.3M | 58.2M | 97.0M | 27.3M |
| Accounts payable | 11.2M | 4.39M | 3.52M | 3.32M | 4.76M | 1.79M | 1.74M | 954.0K | 460.0K |
| Current liabilities | 44.0M | 29.1M | 19.0M | 15.7M | 16.3M | 16.7M | 13.0M | 8.05M | 5.91M |
| Long-term debt | 0 | ||||||||
| Total debt | 0 | 24.6M | 14.7M | 16.1M | 16.4M | ||||
| Total liabilities | 61.0M | 49.8M | 32.1M | 30.5M | 34.4M | 31.9M | 28.2M | 124.6M | 46.9M |
| Shareholders' equity | 505.7M | 510.6M | 307.8M | 231.3M | 319.1M | 256.4M | -73.0M | -27.6M | -19.6M |
| Shares outstanding | 57.6M | 45.8M | 43.1M | 32.6M | 32.2M | 26.7M | 5.18M | 12.5M | 14.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -109.1M | -134.6M | -75.8M | -86.7M | -69.1M | -50.9M | -36.7M | -16.3M | 8.24M |
| Capital spending | -536.0K | -3.79M | -2.77M | -11.5M | -9.11M | -1.00M | -3.20M | -414.0K | -573.0K |
| Free cash flow | -109.6M | -138.4M | -78.6M | -98.2M | -78.2M | -51.9M | -39.9M | -16.7M | 7.66M |
| Cash from investing | -93.0M | -302.4M | 115.7M | -17.1M | -172.7M | -1.00M | -3.20M | -414.0K | 7.67M |
| Cash from financing | 113.0M | 337.3M | 156.8M | 3.08M | 118.1M | 279.0M | -2.19M | 84.6M | 16.0K |
| Share buybacks | 7.50M | -468.0K | 114.7M | -278.1M | -2.27M | ||||
| Change in cash | -89.1M | -99.8M | 196.8M | -100.7M | -123.7M | 227.1M | -42.1M | 67.9M | 15.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 29, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | May 11, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 8, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 26, 2026 | Financing | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 7, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 31, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 20, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 2, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 23, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 8-K · Current report | Jul 2, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| POS AM · Amendment to an effective registration | Feb 28, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 28, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 28, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2025 | Results | SEC |
| POSASR | Feb 28, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Results | SEC |
| 8-K · Current report | Dec 11, 2024 | Financing | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 25, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 15, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 6, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 21, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 23, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 10, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Jun 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 7, 2024 | Offer document | SEC |
| 8-K · Current report | May 24, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 18, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 10, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 29, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 29, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
This page holds 200 of 444 filings. Open Filings
Cap table
Built by 6ix from 4D Molecular Therapeutics, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 55,244,211
- Fully diluted
- 55,266,011
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 55,244,211 | |
| Options and RSUs | 21,800 | Nov 10, 2026 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 55,244,211 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Shawn Tomasello Other companies: Cabaletta Bio, Inc. (Director · Since at least Jul 21, 2023); Kalaris Therapeutics, Inc. (Director · Mar 29, 2022 – Jun 6, 2024 · Past); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); UroGen Pharma Ltd. (Director · Jun 7, 2021 – Jun 7, 2021 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past) | Director · Since at least Dec 10, 2020 |
| August Moretti Other companies: Vivani Medical, Inc. (Member of the Board · Since at least Jun 24, 2026); Cibus, Inc. (Director · Since at least Nov 18, 2024); Depomed Inc (Chief Financial Officer & SVP · Jan 3, 2012 – Mar 31, 2018 · Past); Alexza Pharmaceuticals Inc (Former SVP, CFO, GC & Sec · Mar 8, 2006 – Dec 31, 2011 · Past) | Chief Financial Officer · Dec 10, 2020 – May 15, 2023 · Past |
| Susannah Gray Other companies: AnaptysBio, Inc. (Director · Since at least Mar 26, 2026); Maravai LifeSciences Holdings, Inc. (Director · Since at least May 23, 2024); Theravance Biopharma, Inc. (Director · Since at least May 8, 2024); Morphic Holding Inc (Director · Jun 4, 2024 – Aug 16, 2024 · Past) | Director · Since at least May 21, 2024 |
| John F. Milligan Other companies: Kailera Therapeutics, Inc. (Board Chair · Since at least Apr 16, 2026); Pacific Biosciences of California, Inc. (Chairman of the Board · Since at least Jul 17, 2013); Gilead Sciences, Inc. (President and CEO, Director · Nov 7, 2013 – Nov 27, 2018 · Past) | Executive Chairman · Since at least Dec 10, 2020 |
| Kristian Humer Other companies: Foghorn Therapeutics Inc. (Chief Financial Officer · Since at least Apr 16, 2024); Sensei Biotherapeutics, Inc. (Director · Jul 30, 2021 – May 21, 2025 · Past); Viridian Therapeutics, Inc. (CFO and CBO · Jul 26, 2021 – Feb 8, 2023 · Past) | Chief Financial Officer · Since at least Dec 9, 2025 |
| Nancy Miller-Rich Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Jan 13, 2020); Kadmon Holdings Inc (Director · Aug 13, 2020 – Nov 9, 2021 · Past); Intercept Pharmaceuticals Inc (Director · Apr 24, 2018 – Nov 8, 2023 · Past) | Director · Since at least Dec 10, 2020 |
| Glenn P. Sblendorio Other companies: Mineralys Therapeutics, Inc. (Chairman · Since at least Feb 19, 2026); Amicus Therapeutics Inc (Director · Since at least Jun 5, 2025) | Board Member · Since at least Jan 5, 2026 |
| Charles Theuer Other companies: Oncternal Therapeutics Inc (Director · Jun 7, 2019 – Jun 20, 2024 · Past) | Director · Since at least Dec 10, 2020 |
| Christopher Paul Simms Other companies: IVERIC bio Inc (SVP, Chief Commercial Officer · Aug 2, 2021 – Jul 11, 2023 · Past) | See Remarks · Since at least Dec 9, 2025 |
| Jacob Chacko Other companies: ORIC Pharmaceuticals, Inc. (PRESIDENT AND CEO, Director · Since at least Feb 1, 2021) | Director · Since at least Dec 10, 2020 |
All 20 people
| Person | Seat |
|---|---|
| Ashoo Gupta | VP, Finance and Controller · Since at least Sep 30, 2025 |
| Chris Simms | Chief Commercial & Business Officer · Since at least Mar 18, 2026 |
| David Kirn | Chief Executive Officer, President, and Co-Founder · Since at least Dec 10, 2020 |
| Dhaval Desai | Chief Development Officer · Since at least Sep 2, 2025 |
| Julie Clark | Chief Medical Officer · Since at least Jun 29, 2026 |
| Katy Barglow | Chief Technical Officer · Since at least Mar 18, 2026 |
| Kim Maplestone | Chief Clinical Operations Officer · Since at least Mar 18, 2026 |
| Robert Young Kim | Chief Medical Officer · Mar 24, 2023 – Mar 6, 2025 · Past |
| Scott Bizily | Chief Legal Officer · Since at least Mar 21, 2022 |
| Theresa Janke | Chief of Staff, Co-Founder · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about 4D Molecular Therapeutics, Inc.